

CITATION REPORT

List of articles citing

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion

DOI: 10.1097/00126334-200412150-00006

Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1570-3.

Source: <https://exaly.com/paper-pdf/37744690/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
119	Stability of transmitted drug-resistant HIV-1 species. 2005 , 18, 537-42		27
118	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). 2005 , 6 Suppl 2, 1-61		120
117	Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. 2005 , 77, 337-44		26
116	HIV treatment decisions and transmitted drug resistance. <i>Clinical Infectious Diseases</i> , 2005 , 41, 233-5	11.6	5
115	Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1350-4	11.6	41
114	Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1316-23	11.6	146
113	Resistance testing in drug-naive HIV-infected patients: is it time?. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1324-5	11.6	29
112	Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. 2006 , 80, 3617-23		388
111	Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. 2006 , 101, 845-9		25
110	Progressive multifocal leukoencephalopathy in HIV-2-infected patient. 2006 , 20, 1342-3		7
109	A urine-based approach to scale up HIV testing in drug users. 2006 , 20, 1349-51		1
108	A case of voluntary intoxication with efavirenz and lamivudine. 2006 , 20, 1352-4		6
107	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. 2006 , 20, 21-8		84
106	Is vaginal washing associated with increased risk of HIV-1 acquisition?. 2006 , 20, 1347-8; author reply 1348-9		14
105	Response to correspondence from Hastings et al. entitled 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?' 2006 , 20, 1356-1357		1
104	Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. 2006 , 20, 2233-6		17
103	An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 162-8	3.1	26

102	Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. 2006 , 7, 477-83		29
101	Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. 2006 , 60, 1098-106		7
100	Analysis of HIV-1 sequences before and after co-infecting syphilis. 2006 , 8, 2872-9		8
99	Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. 2006 , 20, 701-10		81
98	Spontaneous HIV-1 replication in a B-lymphoblastoid cell line obtained from an HIV-1-positive patient with undetectable plasma viral load. 2006 , 20, 1340-2		
97	May immunization strategies that target dendritic cells really offer advantages for HIV-1?. 2006 , 20, 1351-2	0	
96	Drug-resistance mutations can be archived very early in HIV primary infection. 2006 , 20, 1337-8		7
95	Reply to: Is vaginal washing associated with increased risk of HIV-1 acquisition? 2006 , 20, 1348-1349		2
94	Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. 2006 , 20, 2231-3		8
93	Will ART rollout in Africa drive an epidemic of drug resistant HIV?. 2006 , 20, 1354-6; author reply 1356-7		7
92	A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. 2006 , 20, 2229-31		36
91	Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 573-81	3.1	84
90	Compartment-specific HIV-1 resting T-cell reservoirs. 2006 , 20, 1338-40		2
89	HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?. 2006 , 20, 1343-5		2
88	Generic screening test for HIV infection. 2006 , 20, 1345-7		1
87	Persistence of drug-resistant HIV-1 and possible implications for antiretroviral therapy. 2006 , 1, 377-391		5
86	Clinical Significance of HIV-1 Drug Resistance Mutations. 2006 , 37, 554-561		
85	Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 121-4	1.6	23

84	Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. 2007 , 81, 7620-8		84
83	Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 43-50	1.6	1
82	A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. 2007 , 4, e36		134
81	Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. 2007 , 21, 1365-7		7
80	Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. 2007 , 21, 1368-70		5
79	Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. 2007 , 21, 1363-5		19
78	[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]. 2007 , 132, 977-82		8
77	Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naïve patients. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 1783-8	9.7	24
76	Transmitted HIV-1 drug resistance: are we seeing just the tip of an epidemiological iceberg?. <i>Journal of Infectious Diseases</i> , 2007 , 196, 336-8	7	6
75	The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. 2007 , 81, 3037-41		97
74	Primary HIV Infection, phylogenetics, and antiretroviral prevention. <i>Journal of Infectious Diseases</i> , 2007 , 195, 924-6	7	13
73	Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. 2007 , 6, 188-97		2
72	Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 1047-56	5.1	101
71	Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. <i>Journal of Infectious Diseases</i> , 2007 , 195, 399-409	7	34
70	Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 517-24	5.1	59
69	Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. 2007 , 81, 13598-607		18
68	Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases. 2007 , 21, 1370-3		13
67	HIV protease resistance and viral fitness. 2007 , 2, 108-15		13

66	Effect of GB virus C co-infection on response to generic HAART in African patients with HIV-1 clade C infection. 2007 , 21, 1377-9		10
65	Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. 2007 , 21, 1379-81		23
64	Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. 2007 , 21, 1373-5		6
63	Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. 2007 , 8, 1-8		82
62	The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania. 2007 , 21, 1375-7		52
61	Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State. 2007 , 21, 644-52		16
60	Evidence of dual sexual transmission of multi-resistant HIV with two years persistence of resistance to NRTI and NNRTI: a case report. 2008 , 36, 178-80		2
59	British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. 2008 , 9, 563-608		366
58	Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. 2008 , 82, 5510-8		180
57	Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 464-8	5.1	21
56	Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 456-63	5.1	28
55	Short communication: the number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 617-20	1.6	9
54	Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 529-35	1.6	17
53	Sexual networks and the transmission of drug-resistant HIV. 2008 , 21, 644-52		6
52	Treatment of acute HIV-1 infection: are we getting there?. 2008 , 3, 67-74		13
51	Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. 2008 , 3, 166-72		8
50	Using HIV resistance tests in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 218-22	5.1	9
49	HIV testing and monitoring. 2009 , 37, 326-329		1

48	Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naïve seroconverters in Singapore. 2009 , 10, 370-7		21
47	Primary drug resistance in antiretroviral-naïve injection drug users. 2009 , 13, 577-83		7
46	Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?. 2010 , 15, 225-30		1
45	The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns. 2010 , 262, 1-13		9
44	Preparing for HIV Drug Resistance in the Developing World. 2010 , 154-170		1
43	HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. 2010 , 107, 12381-6		90
42	Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1405-14	11.6	41
41	Evolutionary pathways of transmitted drug-resistant HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1467-80	5.1	55
40	Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. <i>PLoS ONE</i> , 2011 , 6, e21189	3.7	28
39	HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. <i>PLoS ONE</i> , 2011 , 6, e23091	3.7	34
38	HIV type-1 drug resistance in treatment-naïve patients monitored using minority species assays: a systematic review and meta-analysis. <i>Antiviral Therapy</i> , 2011 , 16, 9-16	1.6	18
37	Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. 2011 , 12, 250-4		13
36	Modeling the gender-specific impact of vaginal microbicides on HIV transmission. 2011 , 288, 9-20		15
35	Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort. 2011 , 83, 187-95		2
34	Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1055-9	1.6	5
33	Assessments of HIV drug resistance mutations in resource-limited settings. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1058-60	11.6	10
32	Primary antiretroviral drug resistance in newly human immunodeficiency virus-diagnosed individuals testing anonymously and confidentially. 2011 , 17, 283-9		3
31	Differential persistence of transmitted HIV-1 drug resistance mutation classes. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1174-81	7	108

30	HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. <i>Antiviral Therapy</i> , 2012 , 17, 905-13	1.6	5
29	HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. <i>Antiviral Therapy</i> , 2012 , 17, 937	1.6	
28	Prevalence of transmitted HIV-1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America. 2012 , 84, 1514-21		8
27	HIV-1 antiretroviral resistance: scientific principles and clinical applications. 2012 , 72, e1-25		201
26	British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. 2012 , 13, 1-44		132
25	Resistencia transmitida del virus de la inmunodeficiencia humana en pacientes sin exposici3n previa a tratamiento antirretroviral, Cali, Colombia, 2010. 2013 , 17, 19-27		
24	Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba. <i>Infection, Genetics and Evolution</i> , 2013 , 16, 144-50	4.5	20
23	Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 129-35	1.6	21
22	Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil--1996-2012. 2013 , 108, 470-5		6
21	Prevalence and circulation patterns of variant, atypical and resistant HIV in Los Angeles County (2007-2009). 2014 , 86, 1639-47		6
20	Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. 2014 , 11, 105		15
19	Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 896-906	1.6	23
18	Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012). <i>PLoS ONE</i> , 2015 , 10, e0125837	3.7	21
17	Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. <i>Clinical Infectious Diseases</i> , 2015 , 61, 829-36	11.6	30
16	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015 , 212, 28-38	7	49
15	HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015. <i>PLoS ONE</i> , 2016 , 11, e0164156	3.7	11
14	Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 228-36	3.1	43
13	Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 1605-1615	9.7	15

12	HIV-1 drug resistance and resistance testing. <i>Infection, Genetics and Evolution</i> , 2016 , 46, 292-307	4.5	155
11	Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 227-234	5.1	18
10	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1136-1143	11.6	5
9	National survey of pre-treatment HIV drug resistance in Cuban patients. <i>PLoS ONE</i> , 2019 , 14, e0221879	3.7	5
8	Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. <i>PLoS ONE</i> , 2019 , 14, e0213167	3.7	3
7	Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. <i>Southern Medical Journal</i> , 2011 , 104, 95-101	0.6	21
6	Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland. <i>Medical Science Monitor</i> , 2017 , 23, 682-694	3.2	1
5	Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. <i>PLoS ONE</i> , 2010 , 5, e12718	3.7	48
4	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. <i>PLoS ONE</i> , 2016 , 11, e0158620	3.7	12
3	Prevalence of and viral outcomes associated with primary HIV-1 drug resistance. <i>Open AIDS Journal</i> , 2012 , 6, 181-7	0.6	3
2	Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. <i>Antiviral Therapy</i> , 2007 , 12, 1305-1310	1.6	24
1	HIV-1-Resistant Strains during 8-Week on 8-Week off Intermittent Therapy and their Effect on CD4+ T-cell Counts and Antiviral Response. <i>Antiviral Therapy</i> , 2008 , 13, 537-545	1.6	4